Ocular melanoma with extraocular extension
disease diseaseOn this page
Also known as extraocular extension melanomaextraocular extension of melanoma
Summary
Ocular melanoma with extraocular extension (MONDO:0006326) is a cancer and 12 clinical trials. Top therapeutic interventions include sargramostim, axitinib, and dacarbazine. A subtype of ocular melanoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 12
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | ocular melanoma with extraocular extension |
| Mondo ID | MONDO:0006326 |
| NCIT | C7913 |
| UMLS | C0278869 |
| MedGen | 75884 |
| GARD | 0027351 |
| Is cancer (heuristic) | yes |
Also known as: extraocular extension melanoma · extraocular extension of melanoma · ocular melanoma with extraocular extension
Disease family
This is a subtype of ocular melanoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › sensory system cancer › ocular cancer › ocular melanoma › ocular melanoma with extraocular extension
Related subtypes (5): eyelid melanoma, malignant conjunctival melanoma, malignant cornea melanoma, retinal melanoma, uveal melanoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 12.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 10 |
| PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01989572 | PHASE3 | COMPLETED | Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery |
| NCT00020475 | PHASE2 | COMPLETED | Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye |
| NCT00085189 | PHASE2 | COMPLETED | Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma |
| NCT00089063 | PHASE2 | COMPLETED | Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma |
| NCT00121225 | PHASE2 | COMPLETED | Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma |
| NCT00243061 | PHASE2 | COMPLETED | AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma |
| NCT00288041 | PHASE2 | COMPLETED | Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma |
| NCT00329641 | PHASE2 | COMPLETED | Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye |
| NCT00450255 | PHASE2 | COMPLETED | VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery |
| NCT01143402 | PHASE2 | COMPLETED | Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye |
| NCT01533948 | PHASE2 | TERMINATED | Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery |
| NCT01730157 | EARLY_PHASE1 | TERMINATED | Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| SARGRAMOSTIM | 4 | 2 |
| AXITINIB | 4 | 1 |
| DACARBAZINE | 4 | 1 |
| SELUMETINIB | 4 | 1 |
| SORAFENIB | 4 | 1 |
| VORINOSTAT | 4 | 1 |
| GP-100 ANTIGEN | 3 | 3 |
| TYROSINASE | 3 | 3 |
| INCOMPLETE FREUND’S ADJUVANT | 3 | 2 |
| AGATOLIMOD SODIUM | 3 | 1 |
| CEDIRANIB MALEATE | 3 | 1 |
| CHEMBL2369717 | 0 | 3 |
| CHEMBL1574179 | 0 | 1 |
| CHEMBL4463209 | 0 | 1 |
| CHEMBL3939307 | 0 | 1 |